THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS

Authors

  • Alexandra KALOGERAKI Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • D. TAMIOLAKIS Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • Chara MATALLIOTAKI Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • Iliana KARVELA-KALOGERAKI Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • M. KARVELAS-KALOGERAKIS Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • J. SEGREDAKIS Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • V. SINATKAS Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece
  • I. MATALLIOTAKIS Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

Abstract

Objective: The first cytological study examining the expression of P53, BCL2 and MIB 1 expressions in correlation with other clinicopathological parameters in ascitic fluids of patients with serous ovarian carcinomas. Materials and Methods: Fifty women 35-75 years old were diagnosed cytologically and confirmed histologically after operation in the University Hospital of Crete. All carcinomas were serous type and eight(8) of grade I, eighteen(18) of grade II and twenty two (22) of grade III. All carcinomas were staged according to the Figo criteria. Fifteen (15) were of Figo stage III and thirty five (35) were of Figo stage IV. For p53 and bcl-2, staining was evaluated on a semiquantitative scale depending on the number of cells showing positivity. For MIB1, the percentage of positive nuclei was calculated. Main outcome measure(s): The expression of P53, BCL2 and MIB 1 (Ki 67) correlated with tumor grade and Figo stages were estimated by chi-square (x²). Results: The expression of P53 and MIB1 were found to be statistically significant (p<0,005) correlated with Figo stage and tumor grade. A statistical significant correlation was also found between BCL2 expression and tumor Grade ( p<0,005) but not between BCL2 expression and Figo Stage. The study found a high expression of P53 (64%) and MIB1 (72%) and an expression of BCL2 (48%) in ascitic fluid of patients with ovarian carcinoma. A statistically significant correlation between P53 and MIB1 expression correlated with tumor grade and Figo stage (p<0,005) and a statistically significant correlation between BCL2 expression and tumor grade but no with the Figo stage was found (p<0.005).There was a positive correlation between P53 and MIB1 .No significant association was found between P53 and BCL2 expression or MIB1 labeling index. Conclusion(s): Our data show significant differences in the expression of these markers in ovarian tumors and suggest a possible role for these tumor-associated genes as supplemental tools in prognosis and further definition of the biologic potential of these tumors.

Author Biographies

  • Alexandra KALOGERAKI, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Departments of Pathology-Cytopathology

  • D. TAMIOLAKIS, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Departments of Pathology-Cytopathology

  • Chara MATALLIOTAKI, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Department of Gynecology

  • Iliana KARVELA-KALOGERAKI, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Departments of Pathology-Cytopathology

  • M. KARVELAS-KALOGERAKIS, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Departments of Pathology-Cytopathology

  • J. SEGREDAKIS, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Departments of Pathology-Cytopathology

  • V. SINATKAS, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Departments of Pathology-Cytopathology

  • I. MATALLIOTAKIS, Medical School, University of Crete, University Hospital, Heraklion, Crete, Greece

    Department of Gynecology

References

1. Skirnisdottir, Sorbe B, Seidal T, P53, bcl2 and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 2001; 11: 147-158.
2. Preethi T.R., Chacko P, Kesari L, Praseeda I, Chellam VG, Radha Krishna P. Apoptosis in epithelial ovarian tumors. Pathol Res Pract 2002; 198: 273-280.
3. Rowan S, Fisher DE. Mechanisms of apoptotic cell death. Leukemia 1997; 11: 457-465.
4. Levine AJ. P53 :The cellular gate keeper for growth and division. Cell 1997; 88: 323-331.
5. Milner BJ, Allan LA, Eccles DM, Kitchener C, Leonard RCF, Kelly KF. P53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
6. Okamoto A, Sameshima Y, Yokohama S, Terashima Y, Surgimura T, Terrada M, Yakota J, Frequent allelic losses and mutations of the P53 gene in human ovarian cancer. Cancer Res 1991; 83: 978-984.
7. Diebold J, Barretton G, Felchner M, Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996; 105: 341-349.
8. Hockenbery D, Nunez G, Millian C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
9. Marone M, Scambia G, Mozzetti S, Bcl-2 , bax, bcl-xl , and bcl-xs expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998; 4: 517-524.
10. Witty JP, Jensen RA, Johnson AL. Expression and localization of BCL2 related proteins in human ovarian cancers .Anticancer Res, 1998; 18: 1223-1230.
11. Gharizabeh M, Sasaki Y, Araki T, Konishi H, Aihara K, Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analysis. Anatomic Pathol 1997; 107: 451-458.
12. Serov SF, Scully RE, Sobin LH, International histologic classification and staging of tumors: Histologic typing of ovarian tumors. Geneva: World health organization 1973; 91: 37-41.
13. Thomas H, Nasim MM., Sarraf CE, Proliferating cell nuclear antigen (PCNA) immunostaining- a prognostic factor in ovarian cancer? Br J Cancer 1995; 71: 357-362.
14. Viale G,Maisonneuve P, Bonoldi E, Di Bacco A, Bevilacqua P, Panizzoni GA, Radaelli U, Gasparini G, The combined evaluation of P53 accumulation and of Ki-67(MIB 1 )labeling index provides independent information on overall survival of ovarian carcinoma patients. Ann of Oncol.1996; 8: 469-476.
15. Gattoretti G, Becker MH, Key G, Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detects proliferating cells in microwave processed formalin –fixed paraffin sections. J Pathol 1992; 168: 357-363.
16. Bosari S, Viale G, Radaelli U, P53 accumulation in ovarian carcinomas and its prognostic implica-tions.Hum Pathol 1993; 24: 1175-1179.
17. Hartman LC, Podretz KC,Keeny GL, Prognostic significance of P53 immunostaining in epithelial ovarian cancer J Clin Oncol 1994; 12: 64-69.
18. Henriksen R, Srang P, Wilander E. P53 expression in epithelial ovarian neoplasms:Relationships to clinical and pathological parameters.Ki-67 expression the flow cytometry. Gynecol Oncol 1994; 54: 301-306.
19. Van der Zec AGJ, Holleme H, Suurmeijer AJH, Value of P-glycoprotein, glutathione s-transferase pi,c-erb-2, and P53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-78.
20. Levesque MA, Katsaros D, Yu H. Mutant P53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.Cancer 1995;75:1327-38.
21. Mishra SK, Crasta JA. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas. Int J Gynecol Cancer. 2010; 20(4): 537-541.
22. Vereczkey I, Serester O, Dobos J, Gallai M, Szakács O, Szentirmay Z, Tóth E. Molecular characteri-zation of 103 ovarian serous and mucinous tumors.Pathol Oncol Res. 2011; 17(3): 551-559.
23. P. Rescigno, I. Cerillo, R. Ruocco, C. Condello, S. De Placido, and M. Pensabene. New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. Biomed Res Int. 2013; 2013: 852839.
24. Kurman RJ, Shih I-M. Molecular pathogenesis and extra ovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology. 2011; 42(7): 918–931.
25. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clini-copathological features. Virchows Archiv. 2012; 460(3): 237–249.
26. Gursan N, Sipal S, Galik M, Gundogdu C. P53, BCL2, Ki-67 Li (Labelling index) status in benign, proliferative and malignant ovarian surface epithelial neoplasms. The Eurasian Journal of Medicine (EAJM).2009; 41: 10-14.
27. George Coukos, Andrew Berchuck, Robert F. Ozols . Ovarian Cancer: State of the Art and Future Directions in Translational Research. Springer, 2008; pp 99-119.
28. Kalogeraki A, Karvela-Kalogeraki I, Petraki PE, Zois I, Tamiolakis D, Stathopoulos EN, Apoptosis and cell proliferation correlated with tumour grade in peritoneal fluids of patients with serous ovarian cancer. Cytopathology. 2011; 22(6): 383-386.
29. Davidson B, Tropé CG. Ovarian cancer: diagnostic, biological and prognostic aspects Womens Health (Lond Engl) 2014; 10(5): 519-533.
30. Vargas AN. Natural history of ovarian cancer. Ecancermedicalscience. 2014; 8: 465-474.
31. Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, Benedetti Panici P, Ciabatta FR, Tomao S Investigating molecular profiles of ovarian cancer: an update on cancer stem cells J Cancer. 2014; 16; 5(5): 301-310.

Additional Files

Published

2015-06-30

Issue

Vol. 119 No. 2 (2015): The Medical-Surgical Journal

Section

BASIC SCIENCES

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form